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Mast cells (MCs) are tissue resident cells, rich in inflammatory mediators, involved in 
allergic reactions, and with an increasingly recognized role in immunomodulation. 
Dendritic cells (DCs), on the other hand, are central to the determination of immune 
response patterns, being highly efficient antigen-presenting cells that respond promptly 
to changes in their microenvironment. Here, we show that direct cell contact between 
immature monocyte-derived DCs (iDCs) and MC bends DCs toward tolerance induction. 
DCs that had direct contact with MC (MC-iDC) decreased HLA-DR but increased PD-L1 
expression and stimulated regulatory T lymphocytes, which expresses FoxP3+, secrete 
TGF-β and IL-10, and suppress the proliferation of mitogen-stimulated naïve T lympho-
cytes. Furthermore, MC-iDC expressed higher levels of indoleamine-2,3-deoxigenase 
(IDO), a phenomenon that was blocked by treatment of MC with anti-PD-1 or by the 
treatment of DCs with anti-PD-L1 or anti-PD-L2, but not by blocking of H1 and H2 
histamine receptors on DCs. Contact with MC also increased phosphorylated STAT-3 
levels in iDCs. When a STAT-3 inhibitor, JSI-124, was added to the DCs before contact 
with MC, the MC-iDC recovered their ability to induce allogeneic T cell proliferation and 
did not increase their IDO expression.
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inTrODUcTiOn
Mast cells (MCs) are myeloid cells that undergo their final differentiation after migration to skin, 
mucosa, or serosa cavities, where they represent a heterogeneous population. In these tissues, imma-
ture MCs recruited from circulation mature and reside in proximity to blood vessels, nerves, smooth 
muscle, mucus-producing glands, and hair follicle (1). These niches share the common feature of 
allowing the prompt exposure of MC to environmental stimuli, such as allergens and pathogens (2, 
3). Thus, MCs are among the first cells to interact with antigens and irritants, having a decisive role, 
along with dendritic cells (DCs), in promoting inflammation and modulating the adaptive immune 
response (4–6). As, for example, in asthma, where MCs and DCs cooperate in vivo, through IFN-γ 
production (7), to promote inflammation (8).
In contrast to their proinflammatory role in allergic disorders, an essential MC role in the induc-
tion of immune tolerance has been described in mice (9). In a skin-graft model, donor-specific 
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transfusion-induced tolerance was associated with graft infiltra-
tion by MC and regulatory T cells (Tregs) and could not be induced 
in mice lacking MC (10). On the one hand, in allergic reactions, 
where MC are associated with tissue lesions (11), the existence of 
such a regulatory circuit, where MC infiltration would decrease 
local immune responses, and thus, restrict tissue damage, would 
be beneficial to the organism. On the other hand, in conditions 
such as tumors, where MC infiltration is also frequently described 
(12, 13), the presence of MC-decreasing local immune responses 
would be detrimental and could contribute to the immune eva-
sion, which is the characteristic of tumors.
However, the mechanisms through which MCs contribute to 
tolerance induction are not clearly defined. MCs may directly 
induce regulatory differentiation of T cells (10) or migration of 
immature DCs to lymph nodes (9, 14), and here, we describe yet 
another mechanism: the increase in indoleamine-2,3,-deoxige-
nase (IDO) expression by immature DCs after contact with MC. 
We demonstrate that this increase depends on the interaction of 
the programmed cell death-1 molecule (PD-1), expressed by MC, 
and its DC-expressed ligands, PD-L1 and PD-L2. Finally, we pre-
sent evidence implicating STAT-3 and the non-canonical NF-kB 
pathway in the MC-induced modification of DCs associated with 
their contact-induced ability to activate regulatory T cells (Tregs).
MaTerials anD MeThODs
sample collection and cell separation
This study was approved by the Institutional Ethics Committee 
(ICB-USP 275.307/CEP). After informed consent, peripheral 
blood mononuclear cells (PBMC) were obtained from healthy 
donors by leukapheresis at the Hospital Alemão Oswaldo Cruz, 
São Paulo, Brazil. Mononuclear cells were separated over a den-
sity gradient (d =  1.076) (Ficoll-Paque, Amersham Pharmacia 
Biotech, Uppsala, Sweden) and suspended in Iscove’s Modified 
Dulbecco Medium (IMDM), supplemented with 10% fetal calf 
serum, penicillin (100  U/mL), streptomycin (100 μg/mL), and 
amphotericin B (0.25 μg/mL Gibco©, USA) (I-10).
In Vitro Mc generation
Mast cells were differentiated as described by Saito et al. (15), with 
modifications. Briefly, CD34+ cells from peripheral blood were 
isolated by positive immunomagnetic separation and cultured 
in 24-well plates in 100 μL of METHOCULT™ (Stem Cell) plus 
200  μL of IMDM, supplemented with stem cell factor (SCF), 
Interleukin (IL)-6, and IL-3 (200, 50, and 5 ng/mL, respectively) 
per well. After 2 weeks, 100 μL of METHOCULT™ (Stem Cell) 
plus 200 μL of IMDM supplemented with SCF and IL-6 (200 
and 50  ng/mL, respectively) were added to each well. At week 
4, 1 mL of supplemented IMDM (SCF, 200 ng/mL; IL-6, 50 ng/
mL; insulin–transferrin–selenium solution, Gibco©, catalog no. 
41400-045, 100 μL/mL) was added to each well. At week 6, non-
adherent cells were transferred to a 12-well plate in supplemented 
IMDM [SCF, 100  ng/mL; IL-6, 50  ng/mL; insulin–transferrin–
selenium solution (20%); 20% of 10% BSA in phosphate-buffered 
saline]. Two weeks thereafter, non-adherent cells were transferred 
to six-well plates and cultured with I-10 supplemented with SCF 
(100 ng/mL) and IL-6 (50 ng/mL); 1 week later, the cells were 
harvested.
Mc Phenotype analysis
Cell labeling and flow cytometry acquisition were described 
previously (16). The cells were labeled for CD13, CD117, PD-1 
(Becton Dickinson, San Jose, CA, USA), and FCϵRIα (BioLegend), 
acquired in a FACSCanto II cytometer (Becton Dickinson, USA) 
and analyzed using the FlowJo software 8.7.2 (Tree Star). At least 
20,000 events in the MC gate, determined by forward (FSC) and 
side (SSC) scatters, were acquired per sample.
Monocyte-Derived Dendritic cells 
generation and coculture with Mc
Peripheral blood mononuclear cells from the same donors used 
for MC generation were thawed, separated over a Ficoll-Paque 
gradient and seeded in 24-well plates in I-10 (2.5 × 106 cells/mL). 
After overnight incubation at 37°C, non-adherent cells were 
removed and GM-CSF and IL-4 (both at 50 ng/mL; PeproTech, 
Mexico) were added (17). On day 5, immature DCs were obtained, 
harvested on ice, and cultured in I-10 for further 2 days, either 
alone (iDCs) or cocultured in direct contact with MC (MC-iDC) 
in a 5 iDC:1 MC ratio. On day 7, the cells were harvested and their 
viability (>95%) assessed by trypan blue staining. Alternatively, 
iDCs were cultured at the bottom of a 24-well transwell plate, 
which allowed the passage of soluble mediators through a 0.4-μm 
pore, and MC were seeded in the upper compartment in I-10; 
DCs thus obtained will be identified as TW-iDCs throughout the 
experiments.
Antibodies and inhibitors were added to these cocultures as 
described in each experiment.
evaluation of cD107a expression by 
cD117+ cells
For the detection of CD107a expression, MC submitted to various 
culture conditions (in the presence of PMA 100 nM; coculture 
with iDC; isolated culture) were seeded in a 96-well-plate 
(1 ×  105  MC/well) and after 15  min treated with brefeldin-A 
(10 μg/mL, BD Pharmingen) and with PE-labeled anti-CD107a. 
The cells were incubated at 37°C for 12 h, and then harvested, 
washed with PBS, and labeled with fluorescence-labeled anti-
CD11c and anti-CD117. Cells were acquired, at least 20,000 
events per gate, in a FACSCanto II cytometer (Becton Dickinson, 
USA) and analyzed, using the FlowJo software 8.7.2 (Tree Star).
Dc Phenotype analysis
Cells were stained with fluorescence-labeled antibodies for 
CD11c, HLA-DR, CD80, CD86, and PD-L1. At least 10,000 
events in the DCs (FSC × SSC) gate were acquired per sample. 
The frequency and median fluorescence intensity (MFI) of 
the positive cells for each marker were determined within the 
CD14−CD11c+ population.
T cell Proliferation assay
Allogeneic CD3+ T cells were purified by negative magnetic selec-
tion of CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, 
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and CD235a-positive cells; the recovered CD3+ cells (>95% 
purity) were used in CFSE dilution assays, as described (16).
intracellular staining
For the analysis of CD3+ T lymphocytes, these were harvested, at 
day 5 of culture, from the various cocultures with DCs, labeled 
for FoxP3, TGF-β, and IL-10 expression and analyzed by flow 
cytometry.
The frequency of FoxP3+ cells was analyzed using the 
e-Bioscience Foxp3/Transcription Factor Staining Buffer Set 
(Affymetrix, e-Bioscience, USA) as described in the manu-
facturer’s protocol. Before intracellular staining, the cells were 
labeled with fluorescence-labeled anti-CD4 and anti-CD25 
(Becton Dickinson, USA).
The frequency of IL-10- and TGF-β-producing T cells was 
evaluated using the Protein Transport Inhibitor assay (BD 
Bioscience, USA); the BD GolgiPlug™ (brefeldin-A) was added 
to the culture 6 h before harvesting and labeling the cells with 
fluorescence-labeled anti-CD4, anti-CD25, and for cell viability 
(Life Technologies). After resuspending the cells in BD Perm/
Wash, they were labeled with anti-IL-10 and anti-TGF-β (BD 
Bioscience, USA).
Dendritic cells and MC were harvested after 16 h of coculture, 
labeled with anti-CD11c+ (DCs) and anti-CD117+ (MC), and 
after brefeldin-A treatment, also labeled for TGF-β and TNF-α. 
TGF-β production was evaluated by flow cytometry using the 
Protein Transport Inhibitor (BD Bioscience, USA), after 6 h of 
brefeldin-A treatment. For TNF-α detection, labeling of the cells 
was performed after 15  h of brefeldin-A treatment. Data were 
acquired, at least 20,000 events/gate, in a FACSCanto II cytometer 
(Becton Dickinson, USA) and analyzed using the FlowJo software 
8.7.2 (Tree Star).
In Vitro suppression assay
CD3+CD4+CD25+ T Lymphocytes stimulated by the various 
DC preparations were isolated using the Regulatory T Cell 
Isolation Kit (Miltenyi Biotec). These cells were added to violet 
cell tracer (VCT, Life Technologies)-labeled naïve allogeneic T 
lymphocytes (Naïve CD4+ T cells isolation kit, Miltenyi Biotec) 
and seeded in round-bottom 96-well plates at ratios of 1:1 or 
1:5. Phytohemagglutinin-A (PHA – Gibco cat# 10576-015) was 
added to the wells (1% v:v) and after 72 h at 37°C, the cells were 
harvested and analyzed (18). Naïve T cell proliferation was evalu-
ated by VCT dilution in live CD3+ cells. At least 20,000 events per 
gate were acquired per sample.
rT- and qPcr
Total RNA was extracted from CD11c+ isolated by anti-FITC 
microbeads (Miltenyi, no. 130-048-701) using TRIzol (Life 
Technologies). RNA samples were reverse transcribed to 
cDNA using SuperScript® III Reverse Transcriptase (Life 
Technologies) according to the manufacturers’ instructions. 
Real-time PCR for IDO1 (F: GTGCAGGCCAAAGCAGCG and 
R: CCGCAGGCCAGCATCACCT), SOCS3 (F: TCAAGACCT 
TCAGCTCCAAG and R: TGACGCTGAGCGTGAAGAAG), 
SOCS5 (F: ACCCAGAGTTCATTGGATGC and R: CCCACA 
GTATCCTGCAACCT), Rel-B (F: GATTTGCCGAATTAACAAG 
GAA and R: GCTGAACACCACTGATATGTCC), NFkB1 (F: CGT 
GAAGATGCTGCTGGCCG and R: CCAAGTGCAAGGGCG 
TCTGGT), NFkB2 (F: GCTGGGGATCTGCGCCGTTT; R: CGCT 
GCTCGGCCTCCGTAAG), or β-actin (F: CAGGCACCAGGG 
CGTGATGG and R: CGATGCCGTGCTCGATGGGG) was 
performed using SYBR green (Life Technologies) set for an ini-
tial denaturation step at 95°C for 10 min, amplification with 40 
denaturation (95°C, 15 s), annealing (60°C, 15 s), and extension 
cycles (72°C, 30 s); followed by a final extension at 72°C for 6 min. 
PCR results were analyzed using the MXPro3000 software and 
normalized by β-actin expression.
idoleamine-2,3-Deoxigenase Detection by 
Flow cytometry
Cells were harvested after 16 h of coculture, washed twice, and 
labeled for cell viability (Life Technologies), CD11c (IgG1) and 
CD117 (IgG1) expression (BD Bioscience, San Jose, CA, USA). 
Next, the cells were permeabilized (with the protocol used for 
FoxP3 evaluation), mouse serum (2%), and after 15 min at room 
temperature, anti-IDO (IgG2b) (Abcam, USA) (1 μg/106  cells) 
were added. After 40  min at 37°C in a humid chamber, the 
Alexa633-labeled secondary antibody (goat anti-mouse IgG2b, 
eBiosciences) was added. After another 40  min of incubation, 
the cells were washed and acquired in a FACSCanto II cytometer 
(Becton Dickinson, USA). At least 30,000 events per gate were 
acquired per sample; data were analyzed with the FlowJo software 
ver. 8.7.2 (Tree Star).
sTaT-3 Phosphorylation assay
After extracellular staining, DCs were treated with 1% paraform-
aldehyde and kept for 10 min at room temperature. Next, the cells 
were washed with PBS and permeabilized by adding 200 μL of 
ice-cold methanol (90%). These cells were maintained for 30 min 
at −20°C, then washed with PBS, and labeled with anti-p-STAT-3 
(Tyr705) or with the isotype control antibody (BD) for 20 min 
at 4°C. After that, the cells were washed with PBS and the pellet 
resuspended in PBS–BSA 0.05%. The cells were, then, analyzed by 
flow cytometry; at least 20,000 events per DC gate were acquired 
in a FACSCanto II cytometer (Becton Dickinson, USA) and 
analyzed using the FlowJo software 8.7.2 (Tree Star).
Western Blot analysis
Protein extracts, obtained by RIPA lysis of 1 × 106 CD11c+ cells 
separated by magnetic beads, were transferred onto PVDF mem-
branes (20 μg/well) and probed with antibodies against p-STAT-3 
(1:2000, Cell Signaling) or beta-actin (1:30,000, Sigma-Aldrich). 
Proteins of interest were detected with HRP-conjugated rabbit 
anti-mouse IgG antibody (1:10,000, Cell Signaling) and visual-
ized with the Pierce ECL Western blotting substrate (Thermo 
Scientific), according to the manufacturer’s protocol.
PD-1, PD-l1, and PD-l2 Blocking
Mast cells were treated with anti-PD1 (clone MIH4, BD) 
(10 μg/106 cells). After 40 min of treatment, the cells were har-
vested, washed with PBS–BSA 0.1%, and cultured with iDCs.
January 2016 | Volume 7 | Article 94
Rodrigues et al. MC Induce Tolerogenic IDO+ DC
Frontiers in Immunology | www.frontiersin.org
Dendritic cells were treated either with anti-PDL1 (clone 
MIH1, e-Bioscience) or anti-PDL2 (clone MIH18, e-Bioscience) 
(10 μg/106 cells). The cells were incubated at room temperature 
for 40  min, then were harvested, washed with PBS–BSA 0.1%, 
counted, and cocultured with MC in a 5:1 ratio.
Jsi-124, Olopatadine hydrochloride 
(anti-h1), or cimetidine (anti-h2) 
Treatments
Dendritic cells, cultured in six-well plates (106  cells/mL), were 
treated with the STAT-3 inhibitor JSI-124 (Sigma-Aldrich, Saint 
Louis, MO, USA) (0.5  μM) and incubated at 37°C for 16  h. 
Afterward, the cells were washed twice with PBS–BSA 0.1%, 
counted, and cultured with MCs, at the ratio of 5 DCs:1 MC.
In other experiments, before the coculture, DCs were treated 
either with olopatadine hydrochloride (anti-H1) or cimetidine 
(anti-H2) (Sigma-Aldrich, Saint Louis, MO, USA) (50 μg/mL) 
and incubated at 37°C. After 1 h, the cells were washed twice with 
PBS–BSA 0.1% and cultured with MCs at the ratio of 5DCs:1MC.
statistical analysis
One-way ANOVA with the Tukey’s post hoc test or the unpaired 
Student’s t-test were used for comparisons as indicated in each 
experiment; the GraphPad Prism 6.0 was used for the analyses 
and statistical significance was set at p < 0.05.
resUlTs
iDcs surface Phenotype is affected by 
Both Mc soluble Products and cell 
contact
To investigate if MC could affect DCs phenotype and function, 
we differentiated MC in vitro from peripheral blood CD34+ cells. 
After 56  days, 97% of the cells in culture were non-adherent, 
CD13+CD117+, toluidine-blue+ granular MC (Figure 1).
After MC differentiation was confirmed, PBMC from the same 
donor(s) were thawed and adherent cells were cultured with IL-4 
and GM-CSF for 5 days, to induce their differentiation into DC 
(Figure 2). iDCs were, then, left alone, cocultured with autolo-
gous MC either in direct cell contact (MC-iDC), or separated by a 
permeable membrane (TW-iDCs) that would allow the passage of 
soluble mediators or still, stimulated with TNF-α, as a maturation 
control (mDC) (Figure 2B). After 2 days, the cells were harvested 
and analyzed by flow cytometry. Compared to iDCs, TW-iDCs 
displayed increased surface levels of HLA-DR, CD80, CD83, and 
CD86 (Figure 3A).
Contrastingly, MC-iDC expressed decreased levels of HLA-DR 
and CD80, had no significant change in CD86, displayed a ten-
dency to increase in CCR7 expression, and significantly higher 
levels of PD-L1 (Figures  3A,B). As expected, TNF-α induced 
DC maturation-associated changes in the cell surface phenotype 
(Figure 2B).
To evaluate if cell contact in MC-iDC culture resulted in MC 
degranulation, releasing mediators responsible for the DC phe-
notypic changes, we determined the CD107a expression on MC. 
MC alone and those cocultured with iDCs displayed the same low 
levels of CD107a, which, nonetheless, was increased under PMA 
stimulation (Figure 3C).
Mc-iDc stimulate regulatory T cells
However, the surface phenotype of DCs is not always predictive of 
their function (19); so, we evaluated the ability of iDCs, MC-iDC, 
and TW-iDCs to stimulate allogeneic CD3+ T cells. On the one 
hand, TW-iDCs were not more efficient than control iDCs as 
T cell stimulators (Figure  4A), despite their increased levels 
of HLA-DR and CD86 expression. On the other hand, when 
compared to iDCs, MC-iDC induced lower levels of T-cell pro-
liferation (Figure 4A), which in turn had a significantly higher 
expression of CD25 (Figure 4B) and a tendency to lower CD127 
expression (Figure 4C).
It was intriguing that the increased levels of costimulatory 
molecules on the surface of MC supernatant-exposed DCs were 
not paralleled by an enhancement of DC stimulatory activity for 
allogeneic T cells. The high levels of IL-10 secreted by these DCs 
might explain this phenomenon (Figure 4D).
Furthermore, MC-iDC-stimulated T cells expressed high 
levels of FoxP3 (Figure  4E) indicating that MC-exposed iDC 
might be able to induce regulatory T cells (Treg). To confirm this 
regulatory bias, we analyzed the function of the T cells stimulated 
by MC-iDC. We noticed that CD3+CD4+CD25+ cells exposed to 
MC-iDC produced higher levels of TGF-β (Figure 5A) and IL-10 
(Figure 5B) and when isolated from the cocultures, suppressed, 
in a cell dose-dependent manner (Figure 5C), the proliferative 
response to PHA of naïve T lymphocytes.
contact with PD-1 expressed by Mc 
induces expression of iDO by iDcs
IDO expression has been frequently identified as the mechanism 
through which DCs induce Treg (20). Since, the amount of 
in vitro-differentiated MC would not be enough to execute the 
next experiments, we evaluated the human MC lineage, HMC-
1.1, as a model for MC in our settings. Actually, DCs cocultured 
with HMC-1.1 (HMC-iDC) displayed the same features as those 
exposed to CD34+ stem cell-derived MC: they were poor triggers 
of allogeneic T cell proliferation (Figure 6A), stimulated T cells 
to express high levels of FoxP3 (Figure 6B) and to produce high 
levels of TGF-β and IL-10 (Figures 6C,D). Finally, such as those 
cocultured with primary MC, T cells cocultured with HMC-1.1 
induced CD3+CD4+CD25+ cells, that when isolated from the 
coculture, were also able to suppress the naïve T cell proliferation 
in response to PHA (Figure 6E).
Having determined that HMC-1.1 cells were equivalent to 
in vitro-differentiated MC, we performed the next experiments 
using this cell line as a model for MC. When evaluating the 
expression of IDO by iDCs (CD11c+ cells isolated from the cul-
tures), we found that when cultured alone, these cells present no 
mRNA for IDO (Figure 6F) and only very low levels of the pro-
tein (Figure 6G). However, when isolated from the coculture with 
HMC-1.1, they expressed high levels of the message (Figure 6F) 
and of the protein (Figure 6G).
To evaluate whether the production of IDO was dependent on 
histamine, we treated the iDC with either an H1-receptor or an 
FigUre 1 | Phenotype of in vitro-differentiated Mc and of the hMc-1.1 cell line. Adult peripheral CD34+ cells were isolated using immunomagnetic beads 
and induced to differentiate into MC, as described. (a) Morphology of the in vitro cells after 8 weeks, showing toluidine blue staining, similar to that of the human 
mastocytoma line HMC-1.1. (B) Representative flow cytometry analysis showing CD13+ cells and within those, c-kit+, and FCϵRIα+ cells (dotted lines represent 
unstained cells). (c) Comparison of the immunophenotype of in vitro-differentiated MC (n = 10) and cells of the HMC-1.1 line.
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H2-receptor blocker before the coculture. Neither blocker affected 
the expression of IDO by the iDCs, which, again, only expressed 
the enzyme after coculture with HMC-1.1 (Figures 7A,B).
Furthermore, to exclude the role of other soluble mediators, 
potentially released by the HMC-1.1 cells (but not likely, since no 
evidence of degranulation was detected – Figure 3), they were 
treated with the Ca2+ channel-blocker, sodium cromolyn, before 
coculture. The dose of 400 μg/mL of sodium cromolyn did block 
HMC-1.1 degranulation (Figure  7C) but had no effect on the 
ability of these cells to induce IDO expression after coculture with 
the MC lineage (Figure 7D).
One could argue that the increased production of IDO 
could be due to an increase in TGF-β in the microenvironment. 
However, there was no significant increase in either TGF-β+ DC 
(Figure  7E) or TGF-β+ HMC-1.1 (Figure  7F) cells after their 
coculture.
Among the surface molecules associated with regulation in the 
immune system, PD-1 was a possible candidate. Its expression by 
cells of the MC lineage has been reported (21) and was detected 
on both, our in vitro-differentiated MC and on cells of HMC-1.1 
lineage (Figure 8A). Furthermore, both PD-1 ligands, PD-L1 and 
PD-L2, were expressed by the iDCs (Figures 8B,C), which, after 
contact with MC (both primary and of the lineage), displayed 
increased levels of PD-L1 (Figures 3A,B and 8B).
Thus, HMC-1.1 cells were treated, or not, with anti-PD-1 
before coculture with iDC and the phenotype of the resulting 
FigUre 2 | Dc differentiation and maturation. (a) Phenotype changes during DC differentiation (n = 4), ***p < 0.001, **p < 0.01 vs. monocytes; (B) DCs 
phenotype changes after DCs maturation induced by TNF-alpha treatment for 48 h (n = 4), *p < 0.05 vs. mDCs.
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HMC-iDC determined. Anti-PD-1 treatment of HMC-1.1 
inhibited their ability to induce IDO+ iDCs (both at protein 
and IDO1 mRNA levels) (Figures  8D,F). And confirming 
the role of this molecule, the treatment of iDCs with either 
anti-PD-L1 or anti-PD-L2 also inhibited IDO expression 
(Figure 8E).
PD-1 induces iDO expression on iDcs 
Probably via sTaT-3 signaling
IDO production by DCs is positively regulated by STAT-3 
phosphorylation (22) that is, also, a positive regulator of the non-
canonical NF-kB pathway (22, 23). Coherently, the coculture of 
iDCs with HMC-1.1 cells, increased STAT-3 phosphorylation on 
iDCs, but the same did not occur when HMC-1.1 were treated 
with anti-PD-1 (Figure 9) This was detected by flow cytometry, 
which showed an increased frequency of cells with phosphoryl-
ated STAT-3 (pSTAT-3) among HMC-iDC (Figures 9A–C) and 
confirmed by western blot (Figure  9D). Furthermore, it has 
been reported that p-STAT-3 enhances the expression of Rel-B, 
NFkB1, NFkB2, and SOCS5 (22, 24) genes whose enhanced 
expression was also detected in HMC-iDC (Figure  10A). On 
the one hand, supporting the role of PD-1 as the trigger of an 
enhanced phosphorylation of STAT-3 in the iDCs, we noticed 
that blocking of PD-1 inhibited the enhanced expression of the 
genes (Figure  10A). On the other hand, the level of SOCS-3 
in iDCs was decreased after 2  h of coculture with HMC-1.1 
(Figure 10B), a phenomenon that was blocked by treatment of 
the HMC-1.1 line with anti-PD-1. This last observation is coher-
ent with the reported ability of SOCS-3 to inhibit p-STAT-3 (25) 
and IDO (26).
Finally, to assess, through a different strategy, the role of 
pSTAT-3 in the induction of IDO+ DCs, we treated the iDCs, 
before exposing them to the HMC-1.1, with 0.5 μM cucurbitacin 
(JSI-124), an inhibitor of the STAT-3 pathway (22), as shown in 
Figure 9D. After 16 h of JSI-124 exposure, the DCs were ana-
lyzed for their IDO expression (by qPCR and flow cytometry), 
and a significant decrease in their IDO content was found 
(Figures  9E,F). Furthermore, these JSI-124-treated HMC-iDC 
recovered the ability of untreated iDCs to stimulate allogeneic T 
cell proliferation (Figure 9G).
DiscUssiOn
The data presented here show that MCs, much more than being 
the culprits of acute allergic reactions (27), are able to modulate 
the function of DCs via direct cell contact. Though roles for MC 
FigUre 3 | Dc phenotype after coculture with Mc. (a) Phenotype of DCs (CD14−CD11c+ cells) phenotype cultured alone (iDCs), cocultured with MC (MC-iDC), 
or exposed to MC supernatant in a transwell culture system (TW-iDC); cells were labeled with fluorescent antibodies, the median fluorescence intensity (MFI) was 
determined for each marker and the MFI index calculated by the formula: MFI of the experimental group/MFI of control iDCs (of each independent experiment, 
n = 4); *p < 0.05, **/##p < 0.01, ***/###p < 0.001, * compared to iDC and # compared to MC-iDC. (B) Representative experiment showing the expression of different 
markers (dotted lines represent iDC and continuous lines, MC-iDC). (c) Representative and cumulative data on CD107a expression by MC (CD117+ cells) cultured 
alone (continuous line), in the presence of iDCs (shaded area) or stimulated by PMA (100 nM – dotted line), n = 3; **p < 0.01 vs. untreated MC and vs. MC-iDC. All 
comparisons between groups were performed by one-way ANOVA followed by Tukey.
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beyond those which they play in allergic reactions have been 
recently suggested (28), most reports ascribe these regulatory 
functions to MC soluble products (28–32). The data presented 
here, however, indicate that, in our experiments, MC bend DCs 
toward a tolerogenic function via cell membrane contact between 
PD-1, on MC, and its ligands, PD-L1 and PD-L2, on DCs.
Mast cell soluble products have been shown to affect DCs 
toward a proinflammmatory function (9, 32, 33), and also we 
FigUre 4 | induction of Tregs by Mc-iDc. (a) Immunomagnetic beads-selected CD3+ T cells were labeled with CFSE, stimulated by different cells (iDC n = 7; 
MC-iDC n = 8; TW-iDC n = 4; MC n = 3), at a 10:1 ratio and their proliferation evaluated by dilution of the dye; comparisons were performed by one-way ANOVA 
followed by the Tukey’s multiple comparisons test, (*) comparisons to iDC and (#) comparisons to untreated lymphocytes, */#p < 0.05, **/##p < 0.01. (B) CD25 
expression of T cells stimulated by the various cell populations (iDCs, MC-iDC, TW-iDC, or MC alone); the CD25 expression index was calculated by the formula: (% 
of positive cells × MFI of positive cells)/1000; n = 6. (c) The same as (B), but for CD127 expression; n = 3. (D) Cumulative data on the presence of IL-10 in the 
supernatant of iDC, DCs treated with TNF-α (mDC), cultured in direct contact (MC-iDC) or with 20% MC supernatant (MC supernatant + iDC) (n = 3); MC 
supernatant alone was used as a control; results assessed by the CBA assay; comparison performed by ANOVA followed by Tukey, ***p < 0.01. (e) Representative 
and cumulative data on FoxP3 expression by CD3+CD4+CD25+ T cells after stimulation with iDCs (n = 6), MC-iDC (n = 5), TW-iDCs (n = 5), or MC (n = 7); 
***p < 0.001, compared to iDC, ##p < 0.01, compared to MC-iDC, in one-way ANOVA followed by Tukey.
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FigUre 5 | cytokine production and suppression of mitogen-induced proliferation of naïve T cells by Mc-iDc-stimulated T cells. (a) Representative 
and cumulative data (n = 3) on intracellular TGF-β production by CD4+CD25+ T lymphocytes submitted to different stimuli (none, or coculture with MC, MC-iDC, or 
iDCs). (B) Representative and cumulative data (n = 3) on intracellular IL-10 production by CD4+CD25+ T lymphocytes submitted to different stimuli (none, or 
coculture with MC, MC-iDC, or iDCs). (c) Representative and cumulative data (n = 3) on the effect of MC-iDC-stimulated CD4+CD25+ T lymphocytes upon 
mitogen-induced naïve T cell proliferation; stimulated cells were separated and added to violet cell tracer-labeled naïve CD4+ T lymphocytes stimulated with PHA 
(1% v/v, Life Technologies) at different cell ratios and the dilution of the cell tracer determined by flow cytometry, iDC- or TW-iDC-stimulated CD4+CD25+ were used 
as controls (cumulative data refer to the 1:1 cell ratio); only living CD3+ cells were considered and analyzed by one-way ANOVA, followed by Tukey, *p < 0.05, 
**p < 0.01 vs. iDC; ##p < 0.01 vs. MC-iDC.
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FigUre 6 | also mast cells of the hMc-1.1 induce tolerogenic iDc that show increased iDO expression. (a) Cumulative data (n = 3) on the capacity of 
iDCs cocultured with HMC-1.1 cells (HMC-iDC) to trigger allogeneic T lymphocytes proliferation. (B) Cumulative data (n = 3) on the expression of FoxP3 in T cells 
stimulated by iDC or by HMC-iDC. (c) Evaluation of the TFG-β or IL-10 (D) production by T cells exposed to iDC or HMC-iDC (n = 3). (e) Cumulative data (n = 3) on 
the effect of HMC-iDC-stimulated CD4+CD25+ T lymphocytes [(HMC-1.1-iDC)-Ly] compared to control iDC-stimulated cells [(iDC)-Ly] upon mitogen-induced naïve T 
cell proliferation; DC-stimulated T cells were separated and added to violet cell tracer-labeled naïve CD4+ T lymphocytes stimulated with PHA (1% v/v, Life 
Technologies) in a 1:1 ratio, and the dilution of the cell tracer determined by flow cytometry. (F) Representative dot plot from the CD11c+ isolation and their 
expression of IDO1 by PCR and iDCs were used as control. (g) Representative and cumulative data (n = 5) on IDO expression by iDCs and HMC-iDC; data were 
analyzed by Student’s t-test, *p < 0.05; **p < 0.01.
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noticed that DCs, exposed to MC soluble products, through a 
transwell culture system, show phenotypic changes that suggest 
their maturation. These DCs expressed higher levels of CD86, 
CD83, and HLA-DR.
Interestingly, though, in our experiments, the increased levels 
of costimulatory molecules on the surface of MC supernatant-
exposed DCs were not paralleled by an enhancement of DC 
stimulatory activity for allogeneic T cells. This could be explained 
by the high levels of IL-10 secreted by these DCs and is coher-
ent with data from the literature showing that MC significantly 
reduced inflammatory reactions in graft-versus-host disease 
and in infections, by an IL-10-dependent mechanism (34, 35). 
Thus, tissues rich in MC, such as the mucosa, would be partially 
protected from immune-inflammatory damage, by DC-derived 
IL-10, secreted as result of their exposure to MC soluble media-
tors in a regulatory feedback among MC, DCs, and T cells.
FigUre 7 | Blocking of h1 or h2 receptors on iDc did not inhibit iDO expression by hMc-iDc, neither blocked their degranulation. (a) The total RNA 
of CD11c+ cells left alone (iDC), cultured with HMC-1.1 or cultured with H-1 (olopatadine hydrochloride – 50 μg/mL) or H-2 (cimetidine – 50 μg/mL) receptors-
blocked HMC-1.1, as indicated by the “+” signal below (n = 3). (B) Frequency of CD11c+IDO+ cells, in which iDC were left alone (iDC) (n = 5), cultured with 
HMC-1.1 (HMC-iDC) (n = 5), or cultured with H-1 (olopatadine hydrochloride – 50 μg/mL) or H-2 (cimetidine – 50 μg/mL) receptors-blocked HMC-1.1 (n = 3), as 
indicated by the “+” signal below. (c) HMC-1.1 were left alone, stimulated with PMA (100 nM) or simultaneously stimulated with PMA and treated with sodium 
cromolyn at different concentrations (from 3.75 to 400 μg/mL) and their degranulation was evaluated by the expression of CD107a (n = 2). (D) Sodium cromolyn 
(400 μg/mL)-treated HMC-1.1 cocultured with iDC still induce increase in IDO expression by the iDCs, which was evaluated after 16 h of coculture by flow cytometry 
(n = 3). (e) Frequency of TGF-β+ cells among CD11c+ cells exposed (HMC-iDC) or not to mast cells (iDC) (n = 4). (F) Frequency of TGF-β+ cells among HMC-1.1 
CD117+ cells, exposed (iDC-HMC-1.1) or not to iDC (HMC-1.1). Data were analyzed by one-way ANOVA, followed by Tukey, *p < 0.05 vs. iDC.
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Contrastingly, the surface phenotype of DCs cultured in direct 
contact with MC was characterized by a decreased expression of 
costimulatory molecules and, notably, an increased expression of 
the coinhibitory molecule, PD-L1. This molecule has a relevant 
role in controlling T cell responses through its interactions with 
PD-1 on T lymphocytes (36), but little is known about the conse-
quences of its interactions on the DCs themselves, which express 
both PD-L1 and PD-L2 (37).
Though the phenotype of MC-iDC suggested a poor T-cell 
stimulating ability, the surface phenotype of DCs is not always 
predictive of their function (19). So, in order to assess if the 
phenotype of MC-iDC corresponded to a decreased stimula-
tory function, we tested their ability to induce the proliferation 
of allogeneic T cells, and it was, in fact, poor. Not only that, 
MC-iDC-stimulated T lymphocytes were actually regulatory T 
cells that showed an increased expression of CD25 and FoxP3, 
produced high levels of IL-10 and TGF-β, and, when isolated 
from the cocultures and added to naïve T cells, inhibited their 
response to PHA. Though we did discriminate between the 
expansion of already present Tregs and the differentiation of new 
cells, their actual suppressive ability suggests that they might have 
significant impact on immune responses occurring in their pres-
ence. Actually, this resembles what was already described in mice 
(9), where MC bias DCs to become stimulators of Tregs.
At this point, another issue comes to one’s attention. We 
show that MCs affect the phenotype and function of immature 
DCs, which, usually, remain in the tissues and, thus, should 
have less impact upon the immune response than mature 
FigUre 8 | Mast cells differentiated in vitro and the mast cell lineage hMc-1.1 expressed PD-1 and induced increased expression of PD-l1 on iDc. 
(a) Cumulative data on PD-1 expression by in vitro-differentiated MC and HMC-1.1 cells (n = 5). (B) PD-L1 and (c) PD-L2 expression by iDCs and HMC-iDC 
(n = 5); comparison were performed by the unpaired Student’s t-test, *p < 0.05 vs. iDCs. (D) Representative histogram of the effects on IDO expression by iDCs 
after coculture with HMC-1.1 under different conditions: blocking PD-1 on HMC-1.1, blocking of PD-L1 or of PD-L2 on iDCs. (e) Cumulative data on IDO 
expression by iDCs (CD11c+ cells) cocultured with HMC-1.1 cells; for these cultures, HMC-1.1 were treated or not with anti-PD-1 and iDCs with anti-PD-L1 or 
anti-PD-L2 (10 μg/106 cells) (n = 5); an isotype-matched unrelated mAb was used as control for the treatments. (F) qPCR of IDO1 obtained from the RNA of 
CD11c+ cells isolated by microbeads, from cocultures of iDCs with HMC-1.1 (HMC-iDC) or with anti-PD-1-treated HMC-1.1; data were normalized by β-actin 
expression (iDC n = 6; HMC-iDC n = 6; HMC-iDC treated with anti-PD-1, n = 4); data were compared by one-way ANOVA followed by the Tukey’s post hoc test, 
*/#p < 0.05 and ***p < 0.001 vs. iDCs; ##p < 0.01 and ###p < 0.001 vs. MC-iDC.
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DCs (38). However, one should consider that still immature 
DCs entering a tissue rich in MC might be biased into such 
“tolerogenic” status, which could, in turn, hamper local 
immune responses. Furthermore, it is worth mentioning 
that even though MC-iDCs had decreased levels of various 
maturation-associated molecules, these cells had a marginally 
enhanced CCR7 expression. This expression might increase 
their migratory potential, allowing them to reach lymphoid 
organs and affect the development of T cell responses in vivo. 
However, Dudeck et al. (39) have recently shown a clear posi-
tive impact of MC upon DC maturation and migration. In a 
mouse system, the authors demonstrate that MC-derived TNF 
FigUre 9 | coculture with hMc-1.1 induced increase in p-sTaT-3 content of iDcs and was prevented by anti-PD-1 treatment of hMc-1.1. (a) 
Representative dot-plot showing the increase in p-STAT-3 content of CD11c+ cells (iDCs) after coculture with HMC-1.1. (B) Cumulative data on the frequency of 
CD11c+p-STAT-3+ cells among iDCs (n = 5), HMC-iDC (n = 4), and (anti-PD-1-treated HMC-1.1)-iDCs (n = 4); comparison was performed by one-way ANOVA 
followed by Tukey, *p < 0.05 compared to iDCs, ##p < 0.01 compared to HMC-iDC. (c) Immunoblot for p-STAT-3, STAT-3, and β-actin from iDC, HMC-iDC, or iDC 
cultured with HMC-1.1 treated with PD-1 (HMC-iDC + PD-1). (D) JSI-124 (0.5 μM) inhibited p-STAT-3 expression by IFN-α (20 ng/mL)-stimulated iDC. (e) qPCR of 
IDO1 from the RNA of CD11c+ cells, CD11c+ cultured with HMC-1.1 (HMC-iDC), or with iDC treated with JSI-124 (0.5 μM) and cultured with HMC-1.1 (n = 3), the 
CD11c+ were isolated by microbeads. (F) Frequency of IDO+CD11c+ cells detected by flow cytometry among iDCs or among iDC cultured with HMC-1.1 
(HMC-iDC), treated or not with JSI-124 (0.5 μM) (n = 3). (g) CD3+ T cell proliferation induced by the different cell populations (iDC n = 6; iDC treated with JSI-124, 
n = 3; HMC-iDC, n = 3; HMC-iDC exposed to JSI-124, n = 3); comparison among the groups was performed by one-way ANOVA followed by Tukey; (*p < 0.05) 
compared to iDC and (##p < 0.01) compared to HMC-iDC.
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FigUre 10 | expression of p-sTaT-3 modulated genes by iDcs and hMc-iDc. HMC-1.1-exposed iDC isolated by CD11c+ microbeads demonstrated an 
increased expression of Rel-B, NFkB1, NFkB2, and SOCS5 and a decreased expression of SOCS-3 that could be blocked by anti-PD-1 treatment of HMC-1.1 
cells. (a) After 16 h of coculture, CD11c+ cells exposed to HMC-1.1 or HMC-1.1 treated with anti-PD-1 were isolated, had their total RNA extracted using TRIzol, 
and the expression of Rel-B, NFkB1, NFkB2, and SOCS5 were determined. (B) After 2 h of coculture, we evaluated the expression of SOCS-3 from the isolated 
CD11c+ cells.
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is critical for the maturation of CD8+ DCs and for the activa-
tion of contact allergens-specific CD8+ T cells. Indeed, though 
apparently contradictory, these data are in agreement with the 
already observed ambiguous role for MC in the modulation 
of immune responses, where they have been shown to either 
stimulate or suppress, both innate and acquired immune 
responses (40).
We also noted that MC did not degranulate after contact with 
DCs. This is coherent with the described effect of mouse MC 
upon Tregs induction, which can be inhibited by MC degranula-
tion (41).
It is worth noting that MCs have been described as modulating 
the T cell response patterns, sometimes favoring a Th2 profile (42, 
43), but also of Th1 (44) and Th17 (45). However, this modulatory 
activity has been consistently associated with MC degranulation, 
which we did not detect, whereas the effects we describe were 
induced by direct cell contact between MCs and DCs.
Actually, the induction of Tregs by MC has been already 
reported (9) and is in agreement with the tolerogenic activity 
of MC in transplantation models (10). What our observations 
add, however, is the indication that the stimulation of Tregs by 
MC may not be the result of direct MC-T cell interaction, but a 
consequence of the bias induced on DC by the MC.
Intriguingly, although the induction of Tregs by DCs has been 
reported to be dependent on IL-10 (46, 47), this does not seem to 
be the case here. Though DCs exposed to MC supernatants did 
secrete IL-10, they did not bias T cell differentiation toward the 
regulatory phenotype – while those that had direct contact with 
the MC did induce Tregs, but did not secrete IL-10. In our experi-
ments, in fact, the induction of Treg seemed to be dependent on 
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IDO expression by the DCs, an enzyme whose expression has 
been associated with Treg induction (48) and tolerance in a wide 
range of settings, from maternal–fetal interactions to cancer (20).
Though HMC-1.1 cells, the MC lineage we used, are poor 
producers of granules and histamine (49) and our data suggested 
that soluble products were not responsible for the modifications 
on DCs cocultured with MCs, we investigated if histamine, which 
has been shown to induce IDO expression by DCs (50), was 
involved in their response to MC. We treated DCs with blockers 
of H1 (olopatadine hydrochloride) and H2 (cimetidine) receptors 
and HMC-1.1 cells with the Ca2+ inhibitor, sodium cromolyn, 
and evaluated IDO expression by the DCs. As expected, none of 
these treatments decreased IDO expression by HMC-iDC.
Hence, the modification of DCs by contact with MC had to 
be explained by other mechanisms. Among these, TGF-β has 
been associated with the long-term induction of IDO in DCs (23, 
51), which under the influence of this growth factor extend their 
regulatory functions to other cells (51, 52). However, blocking the 
TGF-β receptor on DCs with anti-CD105 monoclonal antibod-
ies did not affect their IDO expression after coculture with MC. 
Though we cannot exclude a role for TGF-β (which was present in 
coculture supernatants – Figure S1 in Supplementary Material) in 
the suppressive milieu, this observation suggests that the triggering 
of IDO production in HMC-iDC is not dependent of this cytokine.
Another eliciting factor for IDO expression by DCs is recom-
binant soluble CTLA-4 (53), a ligand of B-7 costimulatory mol-
ecules. CTLA-4, however, is not expressed by MC (6), but, PD-1, 
another B-7 ligand is (21). And PD-1 interaction with PD-L1 or 
PD-L2 also has been shown to induce immunosuppression, either 
by causing T cell anergy or regulatory phenotype (37). We show 
here that this interaction can have another consequence: when 
occurring between MC and iDCs, it can induce IDO expression 
by the latter, since HMC-1.1 treated with blocking antibodies 
against PD-1 had their ability to induce IDO expression by iDCs 
abolished. Coherently, the blocking of PD-L1 and PD-L2 on iDCs 
was able to decrease their IDO expression.
Furthermore, HMC–iDC interaction caused an increase in 
p-STAT-3 in DCs, which was blocked by anti-PD-1, an observa-
tion that agrees with the known control of IDO expression by the 
non-canonical NF-kB pathway (23), activated by p-STAT-3 (22).
Also, after interaction with HMC-1.1, we noticed an increase 
in SOCS-5, RelB, NFkB1, and NFkB2 and a decrease in SOCS-3, 
phenomena that are coherent with the activation of p-STAT-3 
in the cells (24, 25). Finally, we blocked STAT-3 activation on 
DCs using an inhibitor, JSI-124, which enhances the canonical 
but impairs the non-canonical NF-kB pathway (22). JSI-124-
treatment of DCs prevented the phenotypic changes induced by 
coculture with HMC-1.1 and the treated iDCs, maintained their 
capacity to stimulate T cell proliferation.
In conclusion, these findings show that MC can affect iDCs 
inducing, by direct cell contact, phenotypic and functional 
changes that favor the activation of Tregs. This bias is associated 
with an increase in IDO expression by the iDCs, which depends 
on the interaction of PD-1 (on MC) with its ligands (PD-L1 and/
or PD-L2 on DCs) and which seems to be mediated by an increase 
in p-STAT-3 in DCs.
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